Accordingly, one of the most recent trials on this topic involving a cohort of 26 NSCLC patients reported that patients whose tumors had a CD8+ lymphocyte count under 886/mm2 showed low RR to ICIs treatment (16.7%, p = 0.046), while patients whose tumors had a CD8+ lymphocyte count between 886 and 1899/mm2 exhibited a high RR (60%, p = 0.017), and NSCLC patients harboring CD8+/CD4+ ratios lower than 2 had a low RR (13.3%), when compared to those harboring ratios higher than 2 (RR ranging between 43% and 50% (p = 0.035)). This evidence concerns the gene CD4 and non-small cell lung carcinoma.